Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of K-001 (Pemafibrate/Tofogliflozin) in Healthy Volunteers
NCT05722262Phase 1Completed
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pemafibrate and tofogliflozin in Nonalcoholic steatohepatitis (NASH) (6 arms). Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Time Point and 1 more. Started Feb 2023; status: completed.
02
Drugs
pemafibratetofogliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05722262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722262.